Investor Relations

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Recent Releases

May 31, 2023
EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 18, 2023
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
May 16, 2023
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 03, 2023
EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments
Apr 26, 2023
EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023

Stern Investor Relations
p. 212.362.1200

Amy Phillips
p. 412.327.9499